Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cocrystal Pharma Inc (COCP)

Cocrystal Pharma Inc (COCP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 113,064
  • Shares Outstanding, K 97,469
  • Annual Sales, $ 2,010 K
  • Annual Income, $ -9,650 K
  • 60-Month Beta 1.24
  • Price/Sales 58.07
  • Price/Cash Flow N/A
  • Price/Book 1.65
Trade COCP with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.04
  • Number of Estimates 2
  • High Estimate -0.03
  • Low Estimate -0.04
  • Prior Year -0.07
  • Growth Rate Est. (year over year) +42.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0600 +5.66%
on 07/27/21
1.4900 -24.83%
on 07/29/21
-0.0800 (-6.67%)
since 07/02/21
3-Month
1.0600 +5.66%
on 07/27/21
3.4600 -67.63%
on 05/04/21
-0.1200 (-9.68%)
since 05/03/21
52-Week
0.7600 +47.37%
on 11/17/20
3.4600 -67.63%
on 05/04/21
-1.2400 (-52.54%)
since 08/03/20

Most Recent Stories

More News
California and NYC Order Mandatory COVID-19 Testing Among Municipal Workers

/PRNewswire/ -- New COVID-19 cases continue to surge throughout , causing municipal governments to spring into action to combat the rising number of the highly infectious Delta variant cases. On Monday,...

TNXP : 0.7136 (-0.89%)
VXRT : 7.97 (-0.25%)
COCP : 1.1250 (-2.17%)
ALT : 9.17 (-0.76%)
SIXW.CN : 0.300 (+1.69%)
SIXWF : 0.2360 (-1.87%)
Cocrystal Pharma's SARS-CoV-2 3CL Protease Lead CDI-45205 Demonstrates Broad-Spectrum Activity Against the SARS-CoV-2 Delta and Gamma Variants

Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company") announces that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2...

COCP : 1.1250 (-2.17%)
Cocrystal Joins Russell Microcap(R) Index

Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery...

COCP : 1.1250 (-2.17%)
Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter

Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery...

COCP : 1.1250 (-2.17%)
Cocrystal's (COCP) Antiviral CDI-45205 Effective Against COVID-19

Cocrystal (COCP) SARS-CoV-2 3CL protease inhibitor, CDI-45205, found to be effective in treating the original and two other variants of the COVID-19 virus. Shares up.

REGN : 574.88 (-0.39%)
LLY : 252.21 (+2.27%)
GILD : 68.40 (+0.07%)
COCP : 1.1250 (-2.17%)
Cocrystal's Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Variants

Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery...

COCP : 1.1250 (-2.17%)
Cocrystal Pharma's Participation in the Noble Capital Markets C-Suite Interview Series is Now Available Online

Cocrystal Pharma, Inc. (Nasdaq: COCP), ("Cocrystal" or the "Company"), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery...

COCP : 1.1250 (-2.17%)
Cocrystal Pharma Announces the Passing of Chairman, CEO and Co-founder Dr. Gary Wilcox

With great sadness, Cocrystal Pharma, Inc. (Nasdaq: COCP), ("Cocrystal" or the "Company") announces that Gary Wilcox, Ph.D., Chairman, CEO and co-founder, suddenly passed away Wednesday, May 26 at the...

COCP : 1.1250 (-2.17%)
OPK : 3.50 (-1.41%)
GPX : 20.36 (+0.05%)
ASXC : 2.31 (-2.94%)
Cocrystal Pharma Reports First Quarter 2021 Financial Results and Provides Business Update

Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery...

COCP : 1.1250 (-2.17%)
Cocrystal Pharma Announces Closing of $40 Million Bought Deal

Cocrystal Pharma, Inc.(Nasdaq: COCP), ("Cocrystal" or the "Company"), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery...

COCP : 1.1250 (-2.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise...

See More

Key Turning Points

3rd Resistance Point 1.2250
2nd Resistance Point 1.1900
1st Resistance Point 1.1700
Last Price 1.1250
1st Support Level 1.1150
2nd Support Level 1.0800
3rd Support Level 1.0600

See More

52-Week High 3.4600
Fibonacci 61.8% 2.4286
Fibonacci 50% 2.1100
Fibonacci 38.2% 1.7914
Last Price 1.1250
52-Week Low 0.7600

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar